|
Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
No Relationships to Disclose |